{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:11:19Z","timestamp":1791403879644,"version":"4.3.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s40265-017-0834-x","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T10:13:43Z","timestamp":1509963223000},"page":"1909-1916","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Ciclosporin Ophthalmic Emulsion 0.1%: A Review in Severe Dry Eye Disease"],"prefix":"10.1007","volume":"77","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,6]]},"reference":[{"issue":"3","key":"834_CR1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jtos.2017.05.005","volume":"15","author":"JD Nelson","year":"2017","unstructured":"Nelson JD, Craig JP, Akpek EK, et al. TFOS DEWS II introduction. Ocul Surf. 2017;15(3):269\u201375.","journal-title":"Ocul Surf."},{"issue":"3","key":"834_CR2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575\u2013628.","journal-title":"Ocul Surf."},{"key":"834_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13436","author":"C Baudouin","year":"2017","unstructured":"Baudouin C, Irkec M, Messmer EM, et al. Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting. Acta Ophthalmol (Copenh). 2017. doi: 10.1111\/aos.13436 .","journal-title":"Acta Ophthalmol (Copenh)."},{"key":"834_CR4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejpb.2017.03.006","volume":"117","author":"F Lallemand","year":"2017","unstructured":"Lallemand F, Schmitt M, Bourges J-L, et al. Cyclosporine A delivery to the eye: a comprehensive review of academic and industrial efforts. Eur J Pharm Biopharm. 2017;117:14\u201328.","journal-title":"Eur J Pharm Biopharm."},{"issue":"3","key":"834_CR5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/ICO.0b013e31825e83f4","volume":"32","author":"P Daull","year":"2013","unstructured":"Daull P, Lallemand F, Philips B, et al. Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. Cornea. 2013;32(3):345\u201354.","journal-title":"Cornea."},{"issue":"8","key":"834_CR6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40267-016-0319-0","volume":"32","author":"KA Lyseng-Williamson","year":"2016","unstructured":"Lyseng-Williamson KA. Cationorm\u00ae (cationic emulsion eye drops) in dry eye disease: a guide to its use. Drugs Ther Perspect. 2016;32(8):317\u201322.","journal-title":"Drugs Ther Perspect."},{"issue":"4","key":"834_CR7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jphp.12075","volume":"66","author":"P Daull","year":"2014","unstructured":"Daull P, Lallemand F, Garrigue JS. Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. J Pharm Pharmacol. 2014;66(4):531\u201341.","journal-title":"J Pharm Pharmacol."},{"issue":"12","key":"834_CR8","first-page":"5053","volume":"57","author":"P Daull","year":"2016","unstructured":"Daull P, Guenin S, Garrigue JS. Mechanism of action of cationic emulsions in the management of ocular surface inflammation and wound healing [abstract]. Invest Ophthalmol Vis Sci. 2016;57(12):5053.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"834_CR9","unstructured":"European Medicines Agency. Ikervis (ciclosporin): EU assessment report. 2015. http:\/\/www.ema.europa.eu\/ema\/ . Accessed 26 Sep 2017."},{"key":"834_CR10","unstructured":"Santen Oy. IKERVIS 1 mg\/mL eye drops, emulsion: EU summary of product characteristics. 2017. http:\/\/www.ema.europa.eu\/ema\/ . Accessed 26 Sep 2017."},{"issue":"2","key":"834_CR11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5114\/ceji.2016.60995","volume":"41","author":"AM Ambroziak","year":"2016","unstructured":"Ambroziak AM, Szaflik J, Szaflik JP, et al. Immunomodulation on the ocular surface: a review. Cent Eur J Immunol. 2016;41(2):195\u2013208.","journal-title":"Cent Eur J Immunol."},{"key":"834_CR12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.exer.2016.10.016","volume":"153","author":"P Daull","year":"2016","unstructured":"Daull P, Feraille L, Barabino S, et al. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye. Exp Eye Res. 2016;153:159\u201364.","journal-title":"Exp Eye Res."},{"issue":"12","key":"834_CR13","first-page":"421","volume":"57","author":"JS Garrigue","year":"2016","unstructured":"Garrigue JS, Daull P, Feraille L, et al. Comparative efficacy of cyclosporine eye drop formulations in a mouse model of dry eye [abstract]. Invest Ophthalmol Vis Sci. 2016;57(12):421.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"5","key":"834_CR14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5301\/EJO.5000952","volume":"27","author":"C Baudouin","year":"2017","unstructured":"Baudouin C, Figueiredo FC, Messmer EM, et al. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol. 2017;27(5):520\u201330.","journal-title":"Eur J Ophthalmol."},{"issue":"4","key":"834_CR15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","volume":"26","author":"A Leonardi","year":"2016","unstructured":"Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26(4):287\u201396.","journal-title":"Eur J Ophthalmol."},{"key":"834_CR16","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5001002","author":"C Baudouin","year":"2017","unstructured":"Baudouin C, Sainz de la Maza M, Amrane M, et al. One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. 2017. doi: 10.5301\/ejo.5001002 .","journal-title":"Eur J Ophthalmol."},{"key":"834_CR17","unstructured":"Leonardi A, Garh\u00f6fer G, Amrane M, et al. Persistence of efficacy of 0.1% ciclosporin A cationic emulsion in subjects with severe keratitis due to dry eye disease [abstract no. EX1-051 plus poster]. In: 32nd Asia-Pacific Academy of Ophthalmology Congress. 2017."},{"issue":"12","key":"834_CR18","first-page":"2871","volume":"57","author":"E Messmer","year":"2016","unstructured":"Messmer E, Leonardi A, Amrane M, et al. Pooling of two randomized phase III clinical trials of ciclosporin 1 mg\/mL cationic emulsion (CsA CE) as a treatment for severe keratitis in patients with dry eye disease (DED) [abstract]. Invest Ophthalmol Vis Sci. 2016;57(12):2871.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"834_CR19","unstructured":"Garrigue JS, Messmer EM, Leonardi A, et al. Meta-analysis of two phase III clinical trials of 0.1% ciclosporin cationic emulsion in dry eye disease patients with severe keratitis [poster 266]. In: 29th Annual Meeting of Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS). 2016."},{"key":"834_CR20","doi-asserted-by":"crossref","unstructured":"Leonardi A, Garh\u00f6fer G, Amrane M, et al. Subgroup analysis of two phase III studies of 0.1% cyclosporine A cationic emulsion (CsA CE) in patients with dry eye disease [abstract no. S064]. Acta Ophthalmol (Copenh). 2016;94(Suppl):S256.","DOI":"10.1111\/j.1755-3768.2016.0552"},{"issue":"12","key":"834_CR21","first-page":"2876","volume":"57","author":"S Doan","year":"2016","unstructured":"Doan S, Pisella PJ, Cochener B, et al. Topical ocular ciclosporin 1 mg\/mL cationic emulsion in patients with dry eye with severe keratitis: experience through the French early access program [abstract]. Invest Ophthalmol Vis Sci. 2016;57(12):2876.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"834_CR22","unstructured":"Santen Pharmaceutical (China) Co. Ltd. IKERVIS 1 mg\/mL eye drops, emulsion: Hong Kong prescribing information. Beijing: Santen Pharmaceutical (China) Co. Ltd.; 2015."},{"key":"834_CR23","unstructured":"Santen Pharmaceutical Korea Co. Ltd. IKERVIS 1 mg\/mL eye drops, emulsion: South Korean prescribing information. Seoul: Santen Pharmaceutical Korea Co. Ltd.; 2017."},{"key":"834_CR24","unstructured":"Santen Pharmaceutical Asia Pte. Ltd. IKERVIS eye drops, emulsion 1 mg\/mL: Singapore prescribing information. Singapore: Santen Pharmaceutical Asia Pte. Ltd.; 2017."},{"key":"834_CR25","unstructured":"Santen (Thailand) Co. Ltd. IKERVIS eye drops, emulsion (ciclosporin 1 mg\/mL): Thailand prescribing information. Bangkok: Santen (Thailand) Co. Ltd.; 2015."},{"issue":"3","key":"834_CR26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jtos.2017.05.009","volume":"15","author":"GD Novack","year":"2017","unstructured":"Novack GD, Asbell P, Barabino S, et al. TFOS DEWS II clinical trial design report. Ocul Surf. 2017;15(3):629\u201349.","journal-title":"Ocul Surf."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0834-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0834-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0834-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T17:24:17Z","timestamp":1570296257000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0834-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":26,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["834"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0834-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}